Clinigen, a global leader in accelerating patient access to critical medicines, has announced a definitive agreement to acquire SSI Strategy, a trusted consulting partner to biotechnology innovators. The transaction is expected to close before the end of the year, pending customary conditions. Until completion, both organisations will continue to operate independently.
The acquisition unites SSI’s strategic consulting expertise and established presence across the U.S. and Europe with Clinigen’s operational reach and experience in clinical trial supply, managed access, and commercialisation. The combined organisation will create a comprehensive partner for biopharma innovators—supporting them from early-stage clinical development through to global market launch.
Building a Global Biopharma Partner
Founded in 2010, SSI Strategy has earned a strong reputation for guiding biotechnology companies through development challenges across more than 15 therapeutic areas, with deep expertise in rare diseases. The company’s adaptive operating model—embedding senior executives and operators directly into biotech teams—will now scale globally through Clinigen’s platform.
The integration of SSI Strategy complements Clinigen’s existing Lifecycle Services offering and enhances its ability to deliver integrated, end-to-end solutions. The deal brings together 200 employees, including 145 specialist consultants in medical, clinical, and regulatory disciplines, and a client portfolio of over 280 biopharma firms.
Leadership Continuity and Strategic Growth
Upon closing, Doug Locke, Chief Executive Officer of SSI Strategy, will continue to lead the organisation, working closely with Clinigen’s leadership to expand service offerings worldwide.
The acquisition strengthens Clinigen’s momentum in the U.S. market and broadens its strategic service portfolio to support a global client base. The partnership positions Clinigen to capture a greater share of the $12–13 billion pharmaceutical lifecycle services market, projected to grow at nearly 10% annually through 2030.
Executive Commentary
Dr. Varun Sethi, CEO of Clinigen, commented:
Our purpose has always been to be the global pathfinder that transforms patient access to critical medicines. This key acquisition is a major step forward in operationalising that purpose by combining the best of both worlds for our clients. With SSI’s incredible strategic depth and our unmatched global operational reach, we will be an even stronger partner across the entire product lifecycle, empowering biopharma clients to bring life-changing medicines to patients faster.
Doug Locke, CEO of SSI Strategy, added:
This is a pivotal moment for SSI Strategy and the clients we serve. Joining forces with Clinigen gives us the global scale and reach to amplify our impact—accelerating innovation, de-risking development, and ensuring more patients can access life-changing therapies sooner.
